Travere Therapeutics (TVTX) grants director stock and options
Rhea-AI Filing Summary
Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.
Travere Therapeutics director Roy D. Baynes received new equity compensation awards. He was granted 4,000 shares of common stock at no cost and a stock option covering 12,000 shares with a strike price of $42.26 per share.
The awards were made as an automatic equity grant under Travere’s 2018 Equity Incentive Plan pursuant to the non-employee director compensation program. The equity award vests over one year, and following the stock grant Baynes directly holds 41,500 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 4,000 shares
Net Buy
2 txns
Insider
Baynes Roy D.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 12,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 4,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 12,000 shares (Direct);
Common Stock — 41,500 shares (Direct)
Footnotes (2)
- F1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
- F2. The equity award vests over a one year period.
Key Figures
Stock grant: 4,000 shares
Option grant size: 12,000 shares
Option exercise price: $42.26 per share
+3 more
6 metrics
Stock grant
4,000 shares
Common stock awarded on May 19, 2026
Option grant size
12,000 shares
Stock option (right to buy) granted May 19, 2026
Option exercise price
$42.26 per share
Conversion/exercise price for stock option
Shares after grant
41,500 shares
Common shares directly held following stock grant
Option exercisability date
May 19, 2027
Exercise date for the stock option
Option expiration
May 19, 2036
Expiration date for the stock option
Key Terms
Automatic equity grant, 2018 Equity Incentive Plan, non-employee director compensation program, Stock option (right to buy)
4 terms
Automatic equity grant financial
"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan"
2018 Equity Incentive Plan financial
"under the Issuer's 2018 Equity Incentive Plan, as amended"
non-employee director compensation program financial
"pursuant to the non-employee director compensation program"
Stock option (right to buy) financial
"Stock option (right to buy) reported as a derivative security"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Travere Therapeutics (TVTX) director Roy D. Baynes report on this Form 4?
Roy D. Baynes reported receiving equity compensation, not buying shares on the market. He was granted 4,000 Travere Therapeutics common shares and a stock option over 12,000 shares as part of the non-employee director compensation program.
What stock options did Roy D. Baynes receive from Travere Therapeutics (TVTX)?
Baynes received a stock option for 12,000 Travere Therapeutics shares. The option has an exercise price of $42.26 per share, becomes exercisable starting on May 19, 2027, and is scheduled to expire on May 19, 2036, subject to plan terms.
Is the Travere Therapeutics (TVTX) Form 4 a market purchase or a compensation grant?
The Form 4 reflects compensation grants, not open-market purchases. Both the 4,000-share stock award and 12,000-share stock option were automatic equity grants under Travere’s 2018 Equity Incentive Plan for non-employee directors, with no cash price paid per share at grant.
How do the Travere Therapeutics (TVTX) director equity awards vest?
The equity award reported for Roy D. Baynes vests over one year. This means the granted stock and associated compensation are earned across a one-year period, consistent with the non-employee director compensation program under Travere’s 2018 Equity Incentive Plan.